We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly and ImmunoGen Seal Antibody-Drug Candidate Deal With $1.7 Billion Potential
Eli Lilly and ImmunoGen Seal Antibody-Drug Candidate Deal With $1.7 Billion Potential
Eli Lilly is picking up ImmunoGen’s camptothecin antibody-drug conjugate (ADC) platform in a $13 million deal that could eventually net ImmunoGen $1.7 billion.